PolyNovo Requests Trading Halt Ahead of NovoSorb Device Trial Results in Neuroischemic Diabetic Wounds

MT Newswires Live

2025/09/12

PolyNovo (ASX:PNV) requested a trading halt for its securities on Friday in respect of a poster made public on the results of a chronic wound investigator-initiated clinical trial comparing the use of NovoSorb biodegradable temporizing matrix device combined with negative pressure wound therapy with the clinical standard-of-care in subjects with neuroischemic diabetic wounds, according to a same-day Australian bourse filing.

NovoSorb is a synthetic, biodegradable device designed to facilitate the growth of skin tissue within a patented polyurethane matrix.

The medical technology company requested the trading halt to remain in place until the release of an announcement or the opening of the market on Sept. 16.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2566294468"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2566294468\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2566294468?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-09-12 11:13","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2566294468","market":"nz","top_or_hot":-1,"title":"PolyNovo Requests Trading Halt Ahead of NovoSorb Device Trial Results in Neuroischemic Diabetic Wounds","media":"MT Newswires Live","content":"<html><body><p> PolyNovo (ASX:PNV) requested a trading halt for its securities on Friday in respect of a poster made public on the results of a chronic wound investigator-initiated clinical trial comparing the use of NovoSorb biodegradable temporizing matrix device combined with negative pressure wound therapy with the clinical standard-of-care in subjects with neuroischemic diabetic wounds, according to a same-day Australian bourse filing.</p><p>NovoSorb is a synthetic, biodegradable device designed to facilitate the growth of skin tissue within a patented polyurethane matrix.</p><p>The medical technology company requested the trading halt to remain in place until the release of an announcement or the opening of the market on Sept. 16.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>PolyNovo Requests Trading Halt Ahead of NovoSorb Device Trial Results in Neuroischemic Diabetic Wounds</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPolyNovo Requests Trading Halt Ahead of NovoSorb Device Trial Results in Neuroischemic Diabetic Wounds\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time smaller\">2025-09-12 11:13</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html><body><p> PolyNovo (ASX:PNV) requested a trading halt for its securities on Friday in respect of a poster made public on the results of a chronic wound investigator-initiated clinical trial comparing the use of NovoSorb biodegradable temporizing matrix device combined with negative pressure wound therapy with the clinical standard-of-care in subjects with neuroischemic diabetic wounds, according to a same-day Australian bourse filing.</p><p>NovoSorb is a synthetic, biodegradable device designed to facilitate the growth of skin tissue within a patented polyurethane matrix.</p><p>The medical technology company requested the trading halt to remain in place until the release of an announcement or the opening of the market on Sept. 16.</p></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"PNV.AU","symbol_name":"POLYNOVO LTD","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2566294468","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2566294468","pubTimestamp":1757646805,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"PolyNovo  requested a trading halt for its securities on Friday in respect of a poster made public on the results of a chronic wound investigator-initiated clinical trial comparing the use of NovoSorb biodegradable temporizing matrix device combined with negative pressure wound therapy with the clinical standard-of-care in subjects with neuroischemic diabetic wounds, according to a same-day Australian bourse filing.NovoSorb is a synthetic, biodegradable device designed to facilitate the growth of skin tissue within a patented polyurethane matrix.The medical technology company requested the trading halt to remain in place until the release of an announcement or the opening of the market on Sept. 16.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"PNV.AU":"POLYNOVO LTD","BK7126":"医疗保健用品","BK7508":"医药生物股"},"translate_title":"PolyNovo要求在NovoSorb设备试验结果导致糖尿病神经缺血性伤口之前暂停交易","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"PNV.AU":0.9},"content_text":"PolyNovo (ASX:PNV) requested a trading halt for its securities on Friday in respect of a poster made public on the results of a chronic wound investigator-initiated clinical trial comparing the use of NovoSorb biodegradable temporizing matrix device combined with negative pressure wound therapy with the clinical standard-of-care in subjects with neuroischemic diabetic wounds, according to a same-day Australian bourse filing.NovoSorb is a synthetic, biodegradable device designed to facilitate the growth of skin tissue within a patented polyurethane matrix.The medical technology company requested the trading halt to remain in place until the release of an announcement or the opening of the market on Sept. 16.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}